Cargando…

Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma

Microvascular invasion (MVI) is presently evaluated as a high-risk factor to be directly relative to postoperative prognosis of hepatocellular carcinoma (HCC). Up to now, diagnosis of MVI mainly depends on the postoperative pathological analyses with H&E staining assay, based on numbers and dist...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yongchao, Fu, Yong, Liu, Changcheng, Wang, Xicheng, You, Pu, Li, Xiuhua, Song, Yanxiang, Mu, Xiaolan, Fang, Ting, Yang, Yang, Gu, Yuying, Zhang, Haibin, He, Zhiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873260/
https://www.ncbi.nlm.nih.gov/pubmed/35210426
http://dx.doi.org/10.1038/s41419-022-04625-y
_version_ 1784657425891065856
author Cai, Yongchao
Fu, Yong
Liu, Changcheng
Wang, Xicheng
You, Pu
Li, Xiuhua
Song, Yanxiang
Mu, Xiaolan
Fang, Ting
Yang, Yang
Gu, Yuying
Zhang, Haibin
He, Zhiying
author_facet Cai, Yongchao
Fu, Yong
Liu, Changcheng
Wang, Xicheng
You, Pu
Li, Xiuhua
Song, Yanxiang
Mu, Xiaolan
Fang, Ting
Yang, Yang
Gu, Yuying
Zhang, Haibin
He, Zhiying
author_sort Cai, Yongchao
collection PubMed
description Microvascular invasion (MVI) is presently evaluated as a high-risk factor to be directly relative to postoperative prognosis of hepatocellular carcinoma (HCC). Up to now, diagnosis of MVI mainly depends on the postoperative pathological analyses with H&E staining assay, based on numbers and distribution characteristics of MVI to classify the risk levels of MVI. However, such pathological analyses lack the specificity to discriminate MVI in HCC specimens, especially in complicated pathological tissues. In addition, the efficiency to precisely define stages of MVI is not satisfied. Thus, any biomarker for both conforming diagnosis of MVI and staging its levels will efficiently and effectively promote the prediction of early postoperative recurrence and metastasis for HCC. Through bioinformatics analysis and clinical sample verification, we discovered that Stathmin 1 (STMN1) gene was significantly up-regulated at the locations of MVI. Combining STMN1 immunostaining with classic H&E staining assays, we established a new protocol for MVI pathological diagnosis. Next, we found that the degrees of MVI risk could be graded according to expression levels of STMN1 for prognosis prediction on recurrence rates and overall survival in early HCC patients. STMN1 affected epithelial-mesenchymal transformation (EMT) of HCC cells by regulating the dynamic balance of microtubules through signaling of “STMN1-Microtubule-EMT” axis. Inhibition of STMN1 expression in HCC cells reduced their lung metastatic ability in recipients of mouse model, suggesting that STMN1 also could be a potential therapeutic target for inhibiting HCC metastasis. Therefore, we conclude that STMN1 has potentials for clinical applications as a biomarker for both pathological diagnosis and prognostic prediction, as well as a therapeutic target for HCC.
format Online
Article
Text
id pubmed-8873260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88732602022-03-17 Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma Cai, Yongchao Fu, Yong Liu, Changcheng Wang, Xicheng You, Pu Li, Xiuhua Song, Yanxiang Mu, Xiaolan Fang, Ting Yang, Yang Gu, Yuying Zhang, Haibin He, Zhiying Cell Death Dis Article Microvascular invasion (MVI) is presently evaluated as a high-risk factor to be directly relative to postoperative prognosis of hepatocellular carcinoma (HCC). Up to now, diagnosis of MVI mainly depends on the postoperative pathological analyses with H&E staining assay, based on numbers and distribution characteristics of MVI to classify the risk levels of MVI. However, such pathological analyses lack the specificity to discriminate MVI in HCC specimens, especially in complicated pathological tissues. In addition, the efficiency to precisely define stages of MVI is not satisfied. Thus, any biomarker for both conforming diagnosis of MVI and staging its levels will efficiently and effectively promote the prediction of early postoperative recurrence and metastasis for HCC. Through bioinformatics analysis and clinical sample verification, we discovered that Stathmin 1 (STMN1) gene was significantly up-regulated at the locations of MVI. Combining STMN1 immunostaining with classic H&E staining assays, we established a new protocol for MVI pathological diagnosis. Next, we found that the degrees of MVI risk could be graded according to expression levels of STMN1 for prognosis prediction on recurrence rates and overall survival in early HCC patients. STMN1 affected epithelial-mesenchymal transformation (EMT) of HCC cells by regulating the dynamic balance of microtubules through signaling of “STMN1-Microtubule-EMT” axis. Inhibition of STMN1 expression in HCC cells reduced their lung metastatic ability in recipients of mouse model, suggesting that STMN1 also could be a potential therapeutic target for inhibiting HCC metastasis. Therefore, we conclude that STMN1 has potentials for clinical applications as a biomarker for both pathological diagnosis and prognostic prediction, as well as a therapeutic target for HCC. Nature Publishing Group UK 2022-02-24 /pmc/articles/PMC8873260/ /pubmed/35210426 http://dx.doi.org/10.1038/s41419-022-04625-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Cai, Yongchao
Fu, Yong
Liu, Changcheng
Wang, Xicheng
You, Pu
Li, Xiuhua
Song, Yanxiang
Mu, Xiaolan
Fang, Ting
Yang, Yang
Gu, Yuying
Zhang, Haibin
He, Zhiying
Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title_full Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title_fullStr Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title_full_unstemmed Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title_short Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
title_sort stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873260/
https://www.ncbi.nlm.nih.gov/pubmed/35210426
http://dx.doi.org/10.1038/s41419-022-04625-y
work_keys_str_mv AT caiyongchao stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT fuyong stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT liuchangcheng stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT wangxicheng stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT youpu stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT lixiuhua stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT songyanxiang stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT muxiaolan stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT fangting stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT yangyang stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT guyuying stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT zhanghaibin stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma
AT hezhiying stathmin1isabiomarkerfordiagnosisofmicrovascularinvasiontopredictprognosisofearlyhepatocellularcarcinoma